DiaSys Corporation (OTCBB: DYXC)a global healthcare products company, announced today that it has signed a new three-year distribution agreement with Labymed S.A., in Guatemala. The agreement guarantees minimum orders of $656,000 for the Company's parasitology and urine sediment workstations and consumable products over the three-year period. Labymed S.A., which was founded in 1978, also represents Beckman Coulter and Instrumentation Laboratory.

Jose Puig, Sales Manager Latin America stated, "We are pleased to be working with Labymed in Guatemala. They will provide DiaSys Corporation with excellent support for sales and technical service."

"Since December 2005,DiaSys Corporation has entered into seven new three-year distribution agreements that guarantee minimum orders of $14.9 million in Latin America. We will continue to extend our sales initiative throughout 2006," said Gregory Witchel, Chief Executive Officer.

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.

Back